TTRX Stock Forecast: Turn Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$8.10
−6.31% on the day

The median 12-month analyst price target for Turn Therapeutics, Inc. is $25. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 24 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$247.5M
Ticker Nerd rank
24/ 100
Median analyst target
$25
Analysts covering
2
Revenue$0.0
Operating income−$1.6M
Net income−$5.8M
Free cash flow−$929K
Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.4%
1M
−22.7%
YTD
+105.5%
1Y
+198.7%
From 52W high
−47.2%
From 52W low
+198.7%
$3
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Turn Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
24/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
83
Momentum
68
Accruals
40
Revisions
29
Quality
26
Growth
25
Volatility
22
Issuance
5

Value (83): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TTRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TTRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26TTRXHigh $26Median $25Low $24

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$24
Low
$25
Median
$26
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Oct 2026WBB SecuritiesUpgradeHold$10
24 Sept 2026LUCID CAPITAL MARKETSInitiatesBuy$24
14 Sept 2026WBB SecuritiesDowngradeSell$10
24 Mar 2026D. Boral CapitalMaintainsBuy$8.00
20 Jan 2026D. Boral CapitalMaintainsBuy—
29 Dec 2025D. Boral CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TTRX.

Market Radar

This page is one stock. Monday covers all of them.

TTRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TTRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Turn Therapeutics, Inc. returned +198.7% against +6.9% for the S&P 500, dividends included.

TTRX vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Jan 26Apr 26Jul 26Oct 26TTRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TTRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
43.5×

Cheaper than 2% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−412.3%

Higher than 3% of US stocks

Return on assets
−56.1%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Turn Therapeutics, Inc. has a market value of $247.5M and an enterprise value of $243.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$8.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$4.5M.

  • Shares outstanding: 29.8M.

  • Turn Therapeutics, Inc. employs 2 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

TTRX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TTRXTurn Therapeutics, Inc.$247.5M24
QTTBQ32 Bio, Inc.$248.2M61
LXEOLexeo Therapeutics, Inc.$245.1M30
EDITEditas Medicine, Inc.$251.7M67
SABSSAB Biotherapeutics, Inc.$255.7M47
EIKNEikon Therapeutics, Inc.$256.4M5
PRLDPrelude Therapeutics, Inc.$257.3M92

Take a look at TTRX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Turn Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TTRX

What is the TTRX stock price forecast for 2026-2027?

The median 12-month analyst price target for Turn Therapeutics, Inc. is $25, with estimates ranging from $24 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TTRX stock a buy right now?

Of the 2 analysts covering Turn Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Turn Therapeutics, Inc. 24 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TTRX?

As at 21 Nov 2026, Turn Therapeutics, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (83 of 100).

Will TTRX stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $25, and Ticker Nerd's factor model ranks Turn Therapeutics, Inc. 24 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TTRX stock forecast for 2030?

No analyst covering Turn Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TTRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $26 over the next 12 months.

How has TTRX stock performed over the past year?

Turn Therapeutics, Inc. returned +198.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Turn Therapeutics, Inc. do?

Turn Therapeutics Inc. is a clinical-stage biotechnology and medical device company focused on developing targeted therapies for dermatology, wound care, and infectious disease. The company’s product portfolio is built around its proprietary PermaFusion platform, which is designed to improve how active ingredients are delivered and perform in topical treatments.

Company

About Turn Therapeutics, Inc.

Turn Therapeutics Inc. is a clinical-stage biotechnology and medical device company focused on developing targeted therapies for dermatology, wound care, and infectious disease. The company’s product portfolio is built around its proprietary PermaFusion platform, which is designed to improve how active ingredients are delivered and perform in topical treatments. Its current programs include non-systemic therapies for inflammatory skin conditions such as atopic dermatitis, along with treatments for nail and wound-related disorders. Turn Therapeutics also maintains a portfolio of FDA-cleared medical devices and works across healthcare settings that address acute and chronic skin conditions, dermatoses, and infection control. Based in Westlake Village, California, the company operates at the intersection of pharmaceuticals and medical devices, supporting clinicians with localized treatment options designed to act directly at the site of disease.

CEO Mr. Bradley E. Burnam · 2 employees · United States · https://turntherapeutics.com